Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares saw an uptick in trading volume on Wednesday . 10,447,476 shares traded hands during mid-day trading, an increase of 299% from the previous session's volume of 2,620,822 shares.The stock last traded at $11.58 and had previously closed at $10.47.
Analyst Ratings Changes
Several research firms have issued reports on DYN. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Robert W. Baird reduced their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. Chardan Capital reduced their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Stifel Nicolaus dropped their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $34.94.
Check Out Our Latest Analysis on DYN
Dyne Therapeutics Price Performance
The company has a market capitalization of $1.59 billion, a P/E ratio of -2.89 and a beta of 1.08. The company's 50-day moving average price is $10.62 and its two-hundred day moving average price is $11.35. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
Insider Buying and Selling
In related news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The shares were bought at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the purchase, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.14% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Dyne Therapeutics
Hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its position in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock worth $29,000 after purchasing an additional 1,900 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after purchasing an additional 2,446 shares during the period. Quarry LP acquired a new position in shares of Dyne Therapeutics in the 1st quarter worth approximately $47,000. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics in the 4th quarter worth approximately $50,000. Finally, Bryce Point Capital LLC acquired a new position in shares of Dyne Therapeutics in the 2nd quarter worth approximately $115,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
